Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Ogura M, et al. Among authors: miyamoto t. J Clin Oncol. 2014 Apr 10;32(11):1157-63. doi: 10.1200/JCO.2013.52.0924. Epub 2014 Mar 10. J Clin Oncol. 2014. PMID: 24616310 Clinical Trial.
Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study.
Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, Tobinai K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Moriuchi Y, Imada K, Miyamoto T, Akinaga S, Tomonaga M, Ueda R. Ishida T, et al. Among authors: miyamoto t. Br J Haematol. 2015 Jun;169(5):672-82. doi: 10.1111/bjh.13338. Epub 2015 Mar 2. Br J Haematol. 2015. PMID: 25733162 Free PMC article. Clinical Trial.
Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.
Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takemoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, Ueda R. Ishida T, et al. Among authors: miyamoto t. J Clin Oncol. 2012 Mar 10;30(8):837-42. doi: 10.1200/JCO.2011.37.3472. Epub 2012 Feb 6. J Clin Oncol. 2012. PMID: 22312108 Clinical Trial.
[Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102)].
Ogiya D, Shibayama H, Nakatani E, Ando K, Suzuki K, Kuroda Y, Uchida T, Maruyama D, Matsumoto M, Matsue K, Iida S, Terui Y, Ri M, Chou T, Aotsuka N, Tabata S, Konishi J, Ohashi K, Shinagawa A, Sugiura I, Kuroda J, Miyamoto T, Ogura M, Tobinai K, Kanakura Y, Hotta T. Ogiya D, et al. Among authors: miyamoto t. Rinsho Ketsueki. 2016;57(11):2311-2318. doi: 10.11406/rinketsu.57.2311. Rinsho Ketsueki. 2016. PMID: 27941278 Clinical Trial. Japanese.
The outcome and characteristics of patients with relapsed adult T cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation.
Kato K, Uike N, Wake A, Yoshimitsu M, Tobai T, Sawayama Y, Takatsuka Y, Fukuda T, Uchida N, Eto T, Nakashima Y, Kondo T, Taguchi J, Miyamoto T, Nakamae H, Ichinohe T, Kato K, Suzuki R, Utsunomiya A; ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Kato K, et al. Among authors: miyamoto t. Hematol Oncol. 2019 Feb;37(1):54-61. doi: 10.1002/hon.2558. Epub 2018 Sep 28. Hematol Oncol. 2019. PMID: 30171618
Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study.
Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Takatsuka Y, Eto T, Miyazaki Y, Hidaka M, Uike N, Miyamoto T, Tsudo M, Sakamaki H, Morishima Y, Suzuki R, Utsunomiya A. Ishida T, et al. Among authors: miyamoto t. Biol Blood Marrow Transplant. 2013 Dec;19(12):1731-9. doi: 10.1016/j.bbmt.2013.09.014. Epub 2013 Sep 30. Biol Blood Marrow Transplant. 2013. PMID: 24090597 Free article.
Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy.
Miyamura K, Miyamoto T, Tanimoto M, Yamamoto K, Kimura S, Kawaguchi T, Matsumura I, Hata T, Tsurumi H, Saito S, Hino M, Tadokoro S, Meguro K, Hyodo H, Yamamoto M, Kubo K, Tsukada J, Kondo M, Aoki M, Okada H, Yanada M, Ohyashiki K, Taniwaki M. Miyamura K, et al. Among authors: miyamoto t. Leuk Res. 2016 Dec;51:11-18. doi: 10.1016/j.leukres.2016.09.009. Epub 2016 Sep 5. Leuk Res. 2016. PMID: 27771544 Clinical Trial.
Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
Sunami K, Matsumoto M, Fuchida SI, Omoto E, Takamatsu H, Adachi Y, Choi I, Fujishima N, Kiguchi T, Miyamoto T, Maeda A, Suzumiya J, Yamamura R, Nagafuji K, Nakazato T, Kuroda Y, Yujiri T, Takamatsu Y, Harada M, Akashi K. Sunami K, et al. Among authors: miyamoto t. Int J Clin Oncol. 2019 Aug;24(8):966-975. doi: 10.1007/s10147-019-01436-8. Epub 2019 Apr 1. Int J Clin Oncol. 2019. PMID: 30937622 Clinical Trial.
Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy.
Yamamoto K, Shinagawa A, DiNardo CD, Pratz KW, Ishizawa K, Miyamoto T, Komatsu N, Nakashima Y, Yoshida C, Fukuhara N, Usuki K, Yamauchi T, Asada N, Asou N, Choi I, Miyazaki Y, Honda H, Okubo S, Kurokawa M, Zhou Y, Zha J, Potluri J, Matsumura I. Yamamoto K, et al. Among authors: miyamoto t. Jpn J Clin Oncol. 2022 Jan 3;52(1):29-38. doi: 10.1093/jjco/hyab170. Jpn J Clin Oncol. 2022. PMID: 34739075 Free PMC article. Clinical Trial.
4,113 results